Skip to content
Vedanta Biosciences enrolls first patient in pivotal phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile Infection
We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.OkI do not consent
Toggle navigation